MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
Congressional Budget Approval
The House and Senate have approved a budget deal that will replace the sequester, at least for next two years. The agreement provides an additional $22 billion for the appropriations committees to allocate to important programs such as the NIH; allocations should be decided by January 15, 2014. While this is good news and causes some relief, we must remember that it is still very important to remind Congress of the importance of supporting the NIH and cancer research as a whole. We must not forget that sequester cuts are still planned for 2016-2020.
As Francis S. Collins wrote in a Washington Post opinion piece, we must invest in the nation's health. "Biomedical research is at a critical juncture – a moment of exceptional opportunities that demand exceptional attention if their promise is to be fully realized," said Collins. "The National Institutes of Health (NIH) is responsible for turning scientific discoveries into better health, but a combination of sequestration-mandated spending cuts and budgets that have not kept pace with biomedical research inflation over the past 10 years has weakened NIH's ability to carry out its mission." Collins goes on to give examples of these discoveries, including The Cancer Genome Atlas, pointing out that without proper funding, these important data collection projects will be of no use if researchers lack the tools to manipulate the data in a necessary manner.
For the time being we can take a breath and be thankful that Congress has delayed budget cuts, though we must keep our eye on the future and strategize on how to make clear the detrimental effect that a lack of funding will have on the field of biomedical research, and the health of our nation. Write a short note to members of the Ohio caucus to reiterate how important this issue is to each of us, to our region, and to our national priorities.
Contact Information for Ohio Senators and Representatives:
Sen. Robert Portman
Sen. Sherrod Brown
Rep. Steve Chabot (District 1)
Rep. Brad Wenstrup (District 2)
Rep. Joyce Beatty (District 3)
Rep. Jim Jordan (District 4)
Rep. Bob Latta (District 5)
Rep. Bill Johnson (District 6)
Rep. Bob Gibbs (District 7)
Rep. John Boehner (District 8
Rep. Marcy Kaptur (District 9)
Rep. Michael Turner (District 10)
Rep. Marcia Fudge (District 11)
Rep. Pat Tiberi (District 12)
Rep. Tim Ryan (District 13)
Rep. David Joyce (District 14)
Rep. Steve Stivers (District 15)
Rep. Jim Renacci (District 16)
Rep. Bob Peterson (District 17)
CASE CCC IN THE NEWS
Tolerability Better With Weekly Paclitaxel
Clinical Oncology News - Dec 2013
As adjuvant therapy for high-risk breast cancer, once-weekly paclitaxel without a growth factor is just as effective–but generally better tolerated–than every-two-week paclitaxel with a growth factor, according to data presented at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO)..."What this tells me is that in terms of efficacy, you have a choice," said lead author G. Thomas Budd, MD, an oncologist at Cleveland Clinic and Case Comprehensive Cancer Center in Ohio. Dr. Budd reported that the main tolerability advantage with the weekly paclitaxel regimen was a significantly reduced risk for grade 3 or 4 neuropathy and musculoskeletal pain.
SAVE THE DATE
Case CCC Annual Scientific Retreat
Please mark your calendars for the Case CCC Annual Scientific Retreat, July 10-11, 2014. More details to come!
Cleveland Clinic Researchers Create Online Colorectal Cancer Risk Calculator
Researchers at Cleveland Clinic have developed a new tool called CRC-PRO that allows physicians to quickly and accurately predict an individual's risk of colorectal cancer, as published in the current edition of the Journal of the American Board of Family Medicine.
CRC-PRO, or Colorectal Cancer Predicted Risk Online, is designed to help both patients and physicians determine when screening for colorectal cancer is appropriate. Current guidelines recommend patients are screened at the age of 50. However, with this new tool, physicians will be better able to identify who is truly at risk and when screenings for patients are necessary.
To develop the calculator, the researchers – led by Brian Wells, MD, PhD, of the Department of Quantitative Health Sciences in Cleveland Clinic's Lerner Research Institute – analyzed data on over 180,000 patients from a longitudinal study conducted at the University of Hawaii. Patients were followed for up to 11.5 years to determine which factors were highly associated with the development of colorectal cancer. [more]
Alex's Lemonade Stand Foundation Pediatric Oncology Student Training Program
ALSF is dedicated to funding pediatric oncology researchers at critical points in their careers. The Pediatric Oncology Student Training (POST) Program is designed for graduate and medical students who have an interest in pediatric oncology research and would like to experience the field first hand. Students train with a pediatric oncology research mentor. Students may join a research project underway in a mentor's lab or begin an original investigation with the mentor.
Deadline: February 10
Now in its seventh year, the National CENter for ReGenerAtive Medicine UnderGraduate StudEnt Summer Program (ENGAGE), accepting applications. The purpose of the program is to promote and support undergraduate students participation in research and creative projects within the field of stem cells and regenerative medicine. Proposed projects will be expected to match the complexity for what is accepted by SOURCE funding. This program is now open to all undergraduate students, not just CWRU students. Mentors have to be full NCRM members in order to qualify for funding. Projects that provide matching funds and reduce the overall cost of the student will be given higher consideration for inclusion into the program.
Deadline: March 28
Cancer Research Institute Irvington Postdoctoral Fellowship Program
The Cancer Research Institute Irvington Postdoctoral Fellowship Program supports qualified young scientists at leading universities and research centers around the world who wish to receive training in cancer immunology. A panel of scientists drawn from our Scientific Advisory Council rigorously evaluates each candidate, the intended sponsor and training environment, and the nature and feasibility of the proposed project. The Institute seeks hypothesis driven, mechanistic studies in both immunology and tumor immunology. The applicant and sponsor must clearly state the potential of the proposed studies to directly impact our understanding of the immune system's role in cancer risk, tumor initiation, progression, metastasis, host response to tumors and/or the treatment of cancer.
Deadline: April 1